NEU (ASX:NEU) DAYBUE Royalties Lift Growth as Sales Rise

Highlights

• NEU (ASX:NEU) reports around growth in net sales and royalty income, driven by DAYBUE traction.

• Commercial partner expansion continues to support Rett syndrome treatment uptake.

• Market attention builds around biotech earnings visibility within the ASX 200 healthcare sector.

NEU (ASX:NEU) continues to grow royalty income from DAYBUE, with rising sales reinforcing its position as a key biotech name in the ASX healthcare sector.

Australian healthcare stocks continue to attract attention as selective biotech names show consistent revenue traction, with NEU (ASX:NEU), a neuroscience-focused biopharmaceutical company, standing out due to its growing royalty stream from its flagship Rett syndrome therapy. In a market that has rotated between sectors across the ASX, Neuren’s steady earnings profile offers a different kind of momentum compared to early-stage biotech peers.

DAYBUE drives commercial momentum

Neuren Pharmaceuticals (ASX:NEU) continues to build its revenue base through royalties generated from DAYBUE (trofinetide), a therapy approved for the treatment of Rett syndrome and commercialised by its partner Acadia Pharmaceuticals.

Rather than directly commercialising the drug, Neuren operates through a licensing model, allowing it to receive royalty payments while its partner manages sales and distribution. This structure reduces operational burden while providing exposure to global commercial growth.

Royalty model supporting scalable earnings

The structure underpinning Neuren’s business remains a key focus for the market.

By partnering with Acadia Pharmaceuticals for DAYBUE’s global rollout, Neuren benefits from a model where revenue growth is driven externally while cost growth remains relatively contained. As the patient base expands, royalty income rises in parallel.

This model has allowed Neuren Pharmaceuticals (ASX:NEU), a clinical-stage neuroscience specialist, to transition into a more revenue-generating phase compared to many early biotech peers that remain heavily dependent on research funding and pipeline milestones.

Within the broader biotechnology segment of the ASX 200, this royalty-driven structure is increasingly seen as a differentiator, particularly when compared with capital-intensive drug development cycles.

Pipeline adds long-term visibility

Beyond DAYBUE, Neuren continues to progress research programs targeting neurodevelopmental conditions such as Fragile X syndrome.

These programs represent earlier-stage opportunities that sit alongside the existing royalty base. While still in development phases, they provide additional pathways for future commercial expansion. The combination of a commercialised product generating royalties and a pipeline of clinical assets gives Neuren a hybrid profile within the ASX healthcare landscape.

Partner execution remains central to growth

A significant driver of Neuren’s earnings trajectory is the performance of its commercial partner, Acadia Pharmaceuticals.

As DAYBUE expands across approved markets, Neuren’s revenue scales in line with product sales. This means that marketing execution, patient awareness, and physician adoption all play indirect but critical roles in shaping Neuren’s financial outcomes.

The continued rollout of the therapy has supported expectations of sustained royalty growth, reinforcing confidence in the underlying commercial model.

Valuation and market sentiment

Neuren Pharmaceuticals (ASX:NEU) has often traded at a premium relative to traditional biotech peers due to its combination of approved product exposure and pipeline optionality.

Market sentiment tends to focus on two key elements:

• Consistency of royalty growth from DAYBUE

• Progress across early-stage neurological programs

This dual focus creates a balance between established revenue visibility and longer-term clinical upside.

As healthcare remains a selectively favoured sector in the broader ASX environment, companies with recurring revenue streams from approved therapies tend to attract increased attention.

Sector backdrop supports biotech focus

The Australian biotech sector has experienced uneven performance across recent cycles, with investor attention shifting toward companies demonstrating both clinical progress and commercial traction.

Neuren fits into this evolving narrative through its royalty-linked model, which provides more predictable income flow compared with pre-revenue biotech names.

Within the ASX 200, healthcare continues to act as a defensive yet growth-oriented segment, particularly for companies with exposure to rare diseases and specialised treatments.

Outlook shaped by execution and uptake

Looking ahead, Neuren’s performance will continue to be shaped by:

• Expansion in DAYBUE patient adoption

• Continued commercial execution by its partner

• Progress across its clinical pipeline

The sustainability of royalty growth will remain a key focus, alongside broader sentiment toward biotech earnings visibility.

While the sector remains inherently linked to clinical and regulatory outcomes, Neuren’s current position reflects a transition toward more established revenue generation within the ASX healthcare space.